eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | barrett esophagus |
| Symptom | C0001418|adenocarcinoma |
| Sentences | 56 |
| PubMedID- 23617672 | It is often difficult to accurately delineate the borders and extent of early-stage esophageal adenocarcinoma in patients with barrett's esophagus using conventional white light endoscopy. |
| PubMedID- 20610142 | In contrast to adenocarcinoma arising from barrett's esophagus in western countries, the major disease phenotype in the asia-pacific region is esophageal squamous cell carcinoma which is attributed to the prevalence of smoking, alcohol, and betel quid chewing. |
| PubMedID- 19660251 | Rapid progression of barrett's esophagus into adenocarcinoma in a combined lung and kidney transplant recipient. |
| PubMedID- 25071359 | Lifetime risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 22219077 | Risk of adenocarcinoma in patients with barrett esophagus is significantly less than previously assumed. |
| PubMedID- 26233550 | Serum 25-hydroxyvitamin d levels and the risk of dysplasia and esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 24570878 | As exemplified in esophageal adenocarcinoma, the early detection of barrett esophagus (be) with low- or high-grade dysplasia (hgd) might represent the most attractive goal to achieve a cure. |
| PubMedID- 26208896 | Background & aims: statins have been reported to protect against esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be). |
| PubMedID- 22241250 | Use of statin medications and risk of esophageal adenocarcinoma in persons with barrett's esophagus. |
| PubMedID- 23338150 | Therefore, telomerase inhibitors may exhibit high potency in the treatment of esophageal adenocarcinoma arising from barrett's esophagus. |
| PubMedID- 26202380 | Overexpression of cd55 from barrett's esophagus is associated with esophageal adenocarcinoma risk. |
| PubMedID- 21857838 | barrett esophagus with progression to adenocarcinoma in multiple family members with attenuated familial polyposis. |
| PubMedID- 21820152 | The findings of this study improve our understanding of the role that chromosomal instability and alterations of tumor suppressor genes such as cdkn2a and oncogenes such as erbb2 play in the progression of intestinal metaplasia to adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 25633286 | Nsaids, statins, low-dose aspirin and ppis, and the risk of oesophageal adenocarcinoma among patients with barrett's oesophagus: a population-based case-control study. |
| PubMedID- 24968432 | Pathological diagnosis was adenocarcinoma with barrett's esophagus. |
| PubMedID- 25621687 | The incidence of esophageal adenocarcinoma arising from barrett esophagus (be) has been rapidly increasing in many western countries over the past few decades.1–3 it also leads to increasing the rate of hospitalization for esophageal adenocarcinoma and causes a serious problem.4 endoscopic surveillance of be, the currently accepted standard, aims to reduce morbidity and mortality by early detection and endoscopic therapy of dysplasia or cancer.5–8 current guidelines from gastroenterology societies recommend endoscopic surveillance of be using white light endoscopy (wle) with targeted biopsies of any endoscopically visible lesions and 4 random quadrant biopsies from every 2 cm of the be segment (seattle protocol).7,9 however, it has been pointed out that this protocol has several limitations, such as time required, low compliance, and increased risk of sampling error.10 therefore, establishment of a more effective surveillance program for detecting dysplastic lesions or those with high malignant potential in be patients is highly desirable. |
| PubMedID- 24681073 | Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with barrett's esophagus. |
| PubMedID- 22302717 | There is a critical need to identify molecular markers that can reliably aid in stratifying esophageal adenocarcinoma (eac) risk in patients with barrett's esophagus. |
| PubMedID- 21309910 | Dysplasia and esophageal adenocarcinoma may arise in patients with barrett's esophagus after fundoplication esophageal ph monitoring showing no acid in esophagus. |
| PubMedID- 26311716 | Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with barrett's oesophagus. |
| PubMedID- 23591735 | We suggest that it may be useful to stratify the risk of adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 23617676 | We report herein a case of adenocarcinoma arising from short-segment barrett's esophagus (ssbe) in a 36-year-old man. |
| PubMedID- 21143918 | There are few clear prognostic indicators of susceptibility to developing oesophageal adenocarcinoma although patients with barrett's oesophagus are thought to be more at risk to developing oesophageal adenocarcinoma. |
| PubMedID- 26068095 | We explored next-generation sequencing to detect mutations with the analytical sensitivity required to predict concurrent high-grade dysplasia (hgd) and esophageal adenocarcinoma (eac) in patients with barrett's esophagus by testing nonneoplastic bim. |
| PubMedID- 20188100 | Medications (nsaids, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 26426603 | Cost-effectiveness decision tree model of endoscopic surveillance for esophageal adenocarcinoma among patients with definite barrett's esophagus. |
| PubMedID- 24221456 | Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with barrett's oesophagus: a systematic review and meta-analysis. |
| PubMedID- 22796132 | Background& aims: proton pump inhibitors and nonsteroidal anti-inflammatory drugs might prevent esophageal adenocarcinoma in patients with barrett's esophagus (be), but there are limited data from clinical trials to support this concept. |
| PubMedID- 23111465 | While some studies suggest ppis result in a significant reduction in the risk of developing dysplasia and adenocarcinoma in patients with barrett's esophagus, others suggest that ppis have no effect. |
| PubMedID- 24570884 | In the united states, the burden of esophageal cancer in 2007 was 16,640 new cases and 14,500 deaths with a 5-year survival rate of only 15%.1 of these cases, 65% were adenocarcinoma associated with barrett esophagus (be). |
| PubMedID- 25708344 | Oesophagectomy is a safe option for early adenocarcinoma arising from barrett's oesophagus. |
| PubMedID- 21995385 | Incidence of adenocarcinoma among patients with barrett's esophagus. |
| PubMedID- 23714382 | Background & aims: recent population-based studies have shown a low risk of esophageal adenocarcinoma (eac) in patients with nondysplastic barrett's esophagus (ndbe). |
| PubMedID- 20698040 | The annual incidence of adenocarcinoma arising from barrett's esophagus (be) is approximately 0.5%. |
| PubMedID- 23243384 | For upper gi tract pathology i-scan assisted in diagnosis or therapy of barrett's esophagus with dysplasia, esophageal adenocarcinoma, hsv esophagitis, gastric malt lymphoma, gastric antral intestinal metaplasia with dysplasia, duodenal follicular lymphoma, and a flat duodenal adenoma. |
| PubMedID- 24737143 | Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 20550712 | The 'exercise and the prevention of oesophageal cancer study' will determine whether 24 weeks of exercise training will lead to alterations in risk factors or biomarkers for oesophageal adenocarcinoma in males with barrett's oesophagus. |
| PubMedID- 20397052 | Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 25843080 | Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with barrett's esophagus(gut 2014;63:1229-1237). |
| PubMedID- 24605249 | Observational studies have shown that non-steroidal anti-inflammatory drugs could reduce the adenocarcinoma incidence in patients with barrett's esophagus by 41%, while statins could reduce the risk by 43%. |
| PubMedID- 24651385 | Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with barrett's esophagus: a meta-analysis. |
| PubMedID- 21115135 | The incidence of esophageal adenocarcinoma among patients with nondysplastic barrett's esophagus has been overestimated. |
| PubMedID- 24212953 | Epidemiologic studies showed that long-term use of ppi was associated with lower rates of dysplasia and adenocarcinoma in patients with barrett's esophagus . |
| PubMedID- 23453294 | Patients: we studied 23 consecutive patients who underwent complete cesd for superficial esophageal carcinoma (22 squamous cell carcinomas and 1 adenocarcinoma associated with barrett's esophagus). |
| PubMedID- 24795040 | Background: proton pump inhibitors (ppis) may reduce the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus. |
| PubMedID- 21593708 | Incidence of esophageal adenocarcinoma with barrett esophagus (be) imposes a decision about therapy management. |
| PubMedID- 22626608 | Background & aims: radiofrequency ablation (rfa) reduces the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be) with high-grade dysplasia (hgd), but its effects in patients without dysplasia are debatable. |
| PubMedID- 22014070 | Among several genetic abnormalities, both kras and erbb2 amplification have been indicated as early events in adenocarcinoma development of barrett's esophagus . |
| PubMedID- 19850156 | Risk of esophageal adenocarcinoma and mortality in patients with barrett's esophagus: a systematic review and meta-analysis. |
| PubMedID- 20937048 | Aim: to assess the effect of 40 mg twice daily esomeprazole (high-dose) on gastric and oesophageal ph and symptoms, and biomarkers relevant to adenocarcinoma, in patients with barrett's oesophagus (bo). |
Page: 1 2